RBC Capital Markets Reiterates Sector Perform Rating for Valeant...


's stock had its "sector perform" rating reissued by equities researchers at RBC Capital Markets in a research note issued to investors on Monday. They currently have a $36.00 target price on the specialty pharmaceutical company's stock.



from Biotech News